Burcu Erbay1, Tonguç Utku Yılmaz2, Ceyla Eraldemir3, Nihal Üren4, Çağrı Tiryaki5, Emel Ergül4, Zafer Utkan2. 1. Clinic of General Surgery, Mustafa Kalemli Tavşanlı State Hospital, Kütahya, Turkey. 2. Department of General Surgery, Kocaeli University School of Medicine, Kocaeli, Turkey. 3. Department of Biochemistry, Kocaeli University School of Medicine, Kocaeli, Turkey. 4. Department of Medical Biology, Kocaeli University School of Medicine, Kocaeli, Turkey. 5. Clinic of General Surgery, Derince Training and Research Hospital, Kocaeli, Turkey.
Abstract
OBJECTIVE: Breast cancer is the most common type of cancer in women worldwide. It is indicated that increased body mass index elevates the risk of developing breast cancer, worsens prognosis, and decreases survival. Several polymorphisms of adiponectin have been shown to affect serum levels of adiponectin and their association with breast cancer. The aim of this study was to investigate the relationship between the adiponectin 45T/G and 276 G/T gene polymorphism and breast cancer in the East Marmara region. MATERIALS AND METHODS: A case-control study was performed in 97 patients with breast cancer and 101 controls in East Marmara in order to evaluate the prevalence of adiponectin gene polymorphism at positions 45 and 276. Patients with familial breast cancer and those who had received chemotherapy or radiotherapy were excluded from the study. Adiponectin gene polymorphisms were investigated using polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP). RESULTS: Adiponectin 45T/G gene genotype frequencies of TT, TG, and GG were 61.9%, 37.1%, and 1% in patients with breast cancer, and 67.3%, 30.7%, and 2% in the control group, respectively. Adiponectin 276G/T gene genotype frequencies of GG, GT, and TT were 45.4%, 45.4%, and 9.3% in patients with breast cancer and 55.4%, 39.6%, and 5.0% in the control group, respectively. CONCLUSION: Our study showed that adiponectin 45T/G and 276 G/T gene polymorphism is not associated with breast cancer risk in patients from the East Marmara region.
OBJECTIVE:Breast cancer is the most common type of cancer in women worldwide. It is indicated that increased body mass index elevates the risk of developing breast cancer, worsens prognosis, and decreases survival. Several polymorphisms of adiponectin have been shown to affect serum levels of adiponectin and their association with breast cancer. The aim of this study was to investigate the relationship between the adiponectin 45T/G and 276 G/T gene polymorphism and breast cancer in the East Marmara region. MATERIALS AND METHODS: A case-control study was performed in 97 patients with breast cancer and 101 controls in East Marmara in order to evaluate the prevalence of adiponectin gene polymorphism at positions 45 and 276. Patients with familial breast cancer and those who had received chemotherapy or radiotherapy were excluded from the study. Adiponectin gene polymorphisms were investigated using polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP). RESULTS:Adiponectin 45T/G gene genotype frequencies of TT, TG, and GG were 61.9%, 37.1%, and 1% in patients with breast cancer, and 67.3%, 30.7%, and 2% in the control group, respectively. Adiponectin276G/T gene genotype frequencies of GG, GT, and TT were 45.4%, 45.4%, and 9.3% in patients with breast cancer and 55.4%, 39.6%, and 5.0% in the control group, respectively. CONCLUSION: Our study showed that adiponectin 45T/G and 276 G/T gene polymorphism is not associated with breast cancer risk in patients from the East Marmara region.
Entities:
Keywords:
Breast cancer; adiponectin; genetic polymorphism
Authors: Puneeth Iyengar; Terry P Combs; Shalin J Shah; Valérie Gouon-Evans; Jeffrey W Pollard; Chris Albanese; Louise Flanagan; Martin P Tenniswood; Chandan Guha; Michael P Lisanti; Richard G Pestell; Philipp E Scherer Journal: Oncogene Date: 2003-09-25 Impact factor: 9.867
Authors: Mehmet Ali Gulcelik; Kadri Colakoglu; Halil Dincer; Lutfi Dogan; Erdinc Yenidogan; Nese Ersoz Gulcelik Journal: Asian Pac J Cancer Prev Date: 2012
Authors: Virginia G Kaklamani; Thomas J Hoffmann; Timothy A Thornton; Geoffrey Hayes; Rowan Chlebowski; Linda Van Horn; Christos Mantzoros Journal: Breast Cancer Res Treat Date: 2013-04-30 Impact factor: 4.872
Authors: M Takahashi; Y Arita; K Yamagata; Y Matsukawa; K Okutomi; M Horie; I Shimomura; K Hotta; H Kuriyama; S Kihara; T Nakamura; S Yamashita; T Funahashi; Y Matsuzawa Journal: Int J Obes Relat Metab Disord Date: 2000-07
Authors: Virginia G Kaklamani; Maureen Sadim; Alex Hsi; Kenneth Offit; Carole Oddoux; Harry Ostrer; Habibul Ahsan; Boris Pasche; Christos Mantzoros Journal: Cancer Res Date: 2008-05-01 Impact factor: 12.701
Authors: Lauren R Teras; Michael Goodman; Alpa V Patel; Mark Bouzyk; Weining Tang; W Ryan Diver; Heather Spencer Feigelson Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-09-01 Impact factor: 4.254
Authors: Tonguç Utku Yılmaz; Levent Trabzonlu; Sertaç Ata Güler; Mehmet Ali Baran; Gökhan Pösteki; Cengiz Erçin; Zafer Utkan Journal: Eur J Breast Health Date: 2018-01-01